In plain terms

The claim being assessed: Injectable CJC-1295 combined with ipamorelin improves physical recovery in adults without diagnosed growth-hormone deficiency.

Where the evidence stands: Γ — Plausible mechanism. There is a believable biological story and partial support, but the causal step has not been demonstrated.

What this mechanism does: The evidence reviewed does not show this mechanism causing the outcome. That does not show it has no effect.

Strongest evidence for it: The preregistered primary-subclaim rule returns SC2 Γ: mechanistic plausibility and partial system support are present, but an exact-combination positive clinical recovery experiment is missing. This is an unproven benefit claim, not a claim that every peptide is ineffective or that future recovery benefit is impossible. Fifty-plus examined originals are mostly component, mechanism, comparator and indication-boundary reports, not fifty trials of the marketed combination.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means

CJC-1295 and ipamorelin can stimulate GH, but the marketed combination has no verified human physical-recovery benefit in this bounded review.

Implications for health and treatment: The preregistered primary-subclaim rule returns SC2 Γ: mechanistic plausibility and partial system support are present, but an exact-combination positive clinical recovery experiment is missing. This is an unproven benefit claim, not a claim that every peptide is ineffective or that future recovery benefit is impossible. Fifty-plus examined originals are mostly component, mechanism, comparator and indication-boundary reports, not fifty trials of the marketed combination.

Limits for individual care: 56 primary reports with 3 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 56 primary reports; claims: 61; verified: 61; unverified: 0. Verification is bounded attribution. Access: 3 partial-body and 53 bounded abstract/status examinations. Literature cutoff: 2026-10-13; source examination UTC date: 2026-10-13. No complete-paper audit or blinded calibration claimed.

Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 4 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

CJC-1295 and ipamorelin can stimulate GH, but the marketed combination has no verified human physical-recovery benefit in this bounded review.

Deciding experiment: A preregistered blinded factorial comparison of formulation-verified CJC-1295, ipamorelin, their exact combination and placebo in a predefined adult recovery setting without diagnosed GH deficiency, with matched rehabilitation and an independently assessed functional recovery endpoint over 4–24 weeks.

Belief versus evidence: The preregistered primary-subclaim rule returns SC2 Γ: mechanistic plausibility and partial system support are present, but an exact-combination positive clinical recovery experiment is missing. This is an unproven benefit claim, not a claim that every peptide is ineffective or that future recovery benefit is impossible. Fifty-plus examined originals are mostly component, mechanism, comparator and indication-boundary reports, not fifty trials of the marketed combination.

Best-supported rival: Indication-specific single-agent effects do not transfer to stacks. PMID12519419 is a placebo-controlled indication-specific positive walking result, while PMID18981485 directly shows GH/IGF-I and mass improvement without functional improvement in healthy older adults. Together they distinguish context-dependent single-agent benefit from both universal axis ineffectiveness and unsupported exact-stack transfer.

COMPETING MECHANISTIC MODELS

Rank 1: Indication-specific single-agent effects do not transfer to stacks (Ε). GH-axis therapies can improve selected clinical function in predefined disease or functional-limitation settings while exact healthy-adult stacks remain untested. Controlled hip-replacement GH results PMID12519419 and capromorelin functional-limitation results PMID19174493 show that the entire axis is not clinically inert. Healthy older MK-677 function was null, pediatric burn safety cannot transfer to critically ill adults, and no exact-stack trial was examined.

Rank 2: Endocrine engagement without established functional recovery (Γ). Hormones and composition can change while useful function remains unestablished or unchanged. The CJC pharmacodynamic reports and MK-677 trial PMID18981485 directly separate engagement/mass from measured function; ROMANA PMID26906526 gives another mass-handgrip dissociation. Selected capromorelin and hip-replacement functional positives prevent a universal claim that axis engagement can never help; biomarker-only evidence cannot prove a complete clinical mechanism.

Rank 3: Concurrent rehabilitation and measurement effects (Γ). Apparent recovery can reflect rehabilitation, practice, fluid-related mass or expectation rather than the exact stack. Controlled identical-training GH-versus-placebo trials PMID1550219 and 7864103 show gains in both arms without an added GH strength effect. The athlete trial PMID20439575 identifies substantial extracellular-water contributions to lean mass. These designs do not independently randomize expectation or rehabilitation absence, and GH sprint capacity plus indication-specific function can improve. The exact stack remains untested.

Rank 4: Stack-specific recovery benefit (Γ). Exact CJC-1295 plus ipamorelin improves clinical physical recovery in adults without diagnosed GH deficiency. Human single-agent GH stimulation and adjacent injury experiments make the mechanism plausible. No examined exact-combination human functional trial; a mechanistic analogy cannot establish recovery, component additivity or net benefit.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Injectable CJC-1295 combined with ipamorelin improves physical recovery in adults without diagnosed growth-hormone deficiency.

The declared clinical causal proposition is represented by SC2. Target engagement, superiority, mechanism, generalization and benefit-harm companions are separately reported and do not substitute for this primary claim.

Selection: position 6 in the registered editorial traffic-priority list; registration timestamp 2026-10-13T15:39:25.266647+00:00. Ranked topics are editorial priorities, not measured worldwide popularity or a preassigned verdict. Registered claim assessed against original sources; no independent blinded calibration is claimed.

Evidence and causal interpretation

Rubric fit: The frozen framework has no dedicated sports-recovery rubric. Rubric 06 is the nearest metabolism/aging fit. Its unchanged literal Δ criterion concerns lifespan/healthspan; a declared clinical adaptation requires a positive controlled functional, return-to-activity or healing endpoint for the exact intervention and registered population. Endocrine markers, tracer synthesis, lean mass alone and cell migration do not substitute. This adaptation never treats a null test or another molecule as a nominal positive threshold crossing.

The direct CJC-1295 studies establish hormone stimulation, not physical recovery. The randomized 2006 dose-escalation report measured GH and IGF-I and short tolerability. The pulsatility report and its later proteomic subset add biological detail, but the latter explicitly reused eleven men from the earlier cohort. These are not several independent clinical recovery trials.

Ipamorelin also has direct human GH pharmacodynamics. Its blinded postoperative-ileus trial, however, did not significantly improve the meal-tolerance primary endpoint. Rat motility positives provide useful translational context but cannot reverse the human result. The human null does not prove that every dose or recovery indication fails.

Comparator studies make the interpretation more nuanced than a blanket rejection of GH biology. GH after elective hip replacement and capromorelin in older adults with mild functional limitation produced selected physical improvements. GH receptor blockade shortened prolonged-exercise endurance in young men. These are different interventions and enrollment contexts, not evidence that the marketed combination works.

The MK-677 original Methods and Results are especially informative: participants received blinded treatment, function included walking, stairs and chair rise, and the study was powered for fat-free mass and visceral fat. Hormones and mass increased while function remained unchanged; limited functional power prevents an equivalence claim. Glycemic changes also show why target engagement and an anabolic label are insufficient to infer net benefit.

The recreational-athlete trial PMID20439575 is a meaningful positive comparator: GH increased sprint capacity over eight weeks, though strength, aerobic endurance and jump power did not significantly improve and the sprint effect disappeared after washout. GH therefore cannot be dismissed as uniformly performance-inactive. Conversely, controlled GH-plus-training studies PMID1550219 and 7864103 added mass or water without extra strength gains. The older-adult factorial trial PMID12425705 found selected male combination benefits alongside frequent adverse effects. These are outcomes of different hormone exposures, not direct CJC-ipamorelin recovery.

Repair-peptide findings retain their own scope. Full-length thymosin beta4 enhanced selected rat and mouse wounds, ligament and fracture mechanics. A new 2026 BPC-157/TB-500 study measured Achilles mechanics directly but found no added combination benefit. Conversely, GH did not improve a rat tendon-bone repair model and prolonged high-dose exposure worsened failure load. These contrasting experiments argue for molecule-, tissue- and stage-specific testing.

The strongest clinical safety boundary is PMID10477776: two randomized trials in prolonged critical illness found higher mortality with high-dose GH. Its severe setting and exposure cannot be converted into a healthy-stack death rate. It nevertheless demonstrates why plausible anti-catabolic activity and endocrine stimulation do not guarantee a favorable clinical outcome. No unverified CJC-associated death allegation is used here.

Tesamorelin is a useful indication boundary. Its HIV-abdominal-adiposity trial used randomized placebo treatment, CT/MRS endpoints and explicit metabolic monitoring; visceral and liver fat improved. The source does not establish healthy-adult recovery enhancement or license transferring its result to CJC-1295/ipamorelin. Sampled black-market molecular variants likewise justify verifying exposure rather than assuming all products match clinical preparations.

Consensus assisted discovery and highlighted missing trials, formulation boundaries and source sections. Its own Teichman citations were labeled Abstract, so that item was not treated as a full-text check. Provider included-paper and research-gap matrix counts are not the number of primary originals examined here. The author independently read selected original Methods/Results for MK-677, CJC proteomics and tesamorelin and reconciled the source limits.

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. The preregistered primary-subclaim rule returns SC2 Γ: mechanistic plausibility and partial system support are present, but an exact-combination positive clinical recovery experiment is missing. This is an unproven benefit claim, not a claim that every peptide is ineffective or that future recovery benefit is impossible. Fifty-plus examined originals are mostly component, mechanism, comparator and indication-boundary reports, not fifty trials of the marketed combination. Sensitivities: weakest-link Α; primary-subclaim Γ; scope-matched Γ.

Decisive-perturbation inventory and causal tally

[3] A blinded placebo-controlled phase 2 intravenous ipamorelin study randomized 117 bowel-resection patients; the key meal-tolerance endpoint and secondary efficacy analyses showed no significant differences. Postoperative ileus, intravenous single-agent dosing and seven-day exposure differ from healthy-adult injectable stacks; nonsignificance does not prove exact equality or refute all doses.

[9] Capromorelin in 395 older adults with mild functional limitation increased IGF-I and lean mass; pooled active groups improved tandem walk at six months and stair climb at 12 months, with glycemic and other adverse signals. The trial stopped early under predefined effect criteria; pooled outcomes, another oral molecule, baseline limitation and longer horizon do not validate healthy-adult CJC-ipamorelin stacks.

[18] A placebo-controlled GH-receptor antagonist trial in twenty healthy men shortened prolonged-exercise time to exhaustion without changing VO2 max. Physiological GH contribution under receptor blockade does not prove benefit from supraphysiological stimulation or the exact peptide combination.

[21] Blinded GH versus placebo in thirty-three older hip-replacement patients improved postoperative four-minute walking distance and selected muscle preservation; most recipients had dose-related side effects. Perioperative GH and underlying osteoarthritis differ from healthy-adult secretagogue stacks; selective strength findings and small sample limit generalization.

[26] The two ROMANA trials randomized 979 lung-cancer cachexia patients; anamorelin increased lean mass but did not improve co-primary handgrip strength, with some severe hyperglycemia. Cancer cachexia and a different oral ghrelin agonist are outside the nominal population; null handgrip is a mass-versus-function boundary rather than proof all axis stimulation fails.

[44] Randomized rat rotator-cuff repair experiments found no benefit of postoperative GH and worse ultimate failure load with prolonged high-dose perioperative GH. The harm is specific to an animal tendon-bone injury and high dosing; it does not prove every human peptide formulation harms tendons.

[46] A thirty-two-rat Achilles repair study found a significant mechanical advantage for TB-500 alone; combined BPC-157/TB-500 did not confer additional benefit over individual treatment. This recent four-arm animal experiment tests another exact stack, not CJC-ipamorelin; small groups and four-week surgical model do not establish human efficacy, safety or dose equivalence.

[51] A blinded 65-person MK-677 trial increased GH, IGF-I and fat-free mass over twelve months but showed no significant strength or function improvement; glucose rose and insulin sensitivity fell. Primary power focused on fat-free mass and visceral fat; secondary functional nulls do not establish equivalence, and another oral agent and older population do not test the exact stack.

[52] A blinded ninety-six-athlete trial found an approximately 3.9 percent GH-associated sprint-capacity increase over eight weeks, with no significant strength, aerobic endurance or jump-power change; lean-mass gain largely reflected extracellular water. Different hormones and a performance endpoint do not test exact peptide recovery; sprint gain was not maintained after six-week washout, and athletic importance and safety were uncertain.

[53] In sixteen young men randomized to identical resistance training with GH or placebo, GH increased fat-free mass and whole-body synthesis but did not add muscle-strength or quadriceps-synthesis gain over twelve weeks. Small trial and recombinant GH differ from the exact stack; similar training gains do not prove all GH-axis exposures ineffective or establish equivalence.

[54] In twenty-three older men assigned to the same resistance training with GH or placebo, fat-free mass and water rose more with GH but muscle protein synthesis and strength increments were similar. The trial supplies a proxy-versus-function and concurrent-training boundary; another molecule and small unequal groups do not test exact-combination recovery.

[55] Two blinded trials in 532 critically ill adults found higher mortality with high-dose GH: 39 versus 20 percent and 44 versus 18 percent; survivors also had longer ventilation and stays. This is a serious randomized safety boundary for high-dose GH in prolonged critical illness, not a measured mortality rate for healthy-adult CJC-ipamorelin stacks.

[56] A blinded 131-person older-adult factorial GH/sex-steroid trial increased lean mass; combined GH-testosterone improved men's VO2 max, while women's strength/endurance were not significantly improved and metabolic or edema-related adverse events were frequent. Different hormone combination, sex-specific responses and 26-week exposure do not establish exact-stack recovery; lean mass alone and correlational changes do not identify mediation.

Tally: 0 positive qualifying study units across scoped subclaims; 20 screened discriminating contrast units. These are not independent causal lines or proof of full-claim necessity/sufficiency. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Zero positive study units qualify the exact healthy-adult CJC-1295 plus ipamorelin recovery claim. Positive functional comparators are intentionally retained without being counted as nominal crossings. Protein spots and endocrine pharmacodynamics are not independent recovery causal lines. A product-identification experiment informs formulation equivalence, not patient outcome prevalence.

No positive field-valid crossing was verified for the registered causal scope in this bounded audit. Pivotal null or negative tests remain informative; their implications depend on comparator quality, target engagement, power and the registered scope.

Cap audit, precedence and Β/Γ/Δ boundary

A related animal experiment can demonstrate repair in its own model, and a different human GH-axis agent can show an indication-specific clinical effect. Neither satisfies the exact combination/population clinical threshold. Universal cap 4 governs the inference from endocrine-only support to recovery, while system and intervention identity govern translation. No cap is re-applied to erase a true same-scope complementary causal set; none was verified for the nominal claim.

Universal six-cap audit: All six universal caps were considered: cell-only inference, unperturbed association, ectopic expression, biomarker-only intervention, forced transfer/seeding, and inherited-to-sporadic scope transfer. Each binds its offered inference; complementary same-scope causal classes are assessed together rather than re-capped in isolation.

Gamma hard-rule audit: Biomarker-only GH/IGF-I support is capped for recovery inference. Cell-only and animal single-species repair support remains system-scoped. Human positive endpoints of different compounds or indications are reported but cannot qualify the exact combination. No full-scope positive trial was examined.

SC1 cap: “Biomarker change without functional/phenotypic change caps at Γ.” Controlled human CJC-1295 and ipamorelin reports establish single-agent GH-axis activity. For the recovery mechanism, these are endocrine biomarkers; the exact combination has no verified human functional result in this search. The biomarker cap is applied to inference from target engagement to recovery, not a denial that pharmacodynamic stimulation occurred.

SC2 cap: “Biomarker change without functional/phenotypic change caps at Γ.” Partial biological support comes from single-agent human pharmacodynamics and related repair experiments. No examined report directly demonstrates a positive functional recovery effect of the exact CJC-1295 plus ipamorelin combination in the registered population. Different hormones, molecules, disease indications and animal injuries do not cross its clinical Δ threshold.

SC3 cap: “Use when the hypothesis is mostly a grand narrative with weak intervention support.” The claim that component evidence establishes all marketed stack benefits remains an unsupported generalization. The new BPC-157/TB-500 four-arm rat study supplies a useful counterexample to automatic additivity, while its own positive single-agent mechanical result retains its rat scope. Approved or studied single-agent indications remain distinct.

SC4 cap: “Use when the hypothesis is mostly a grand narrative with weak intervention support.” A broad net-benefit claim across promoted healthy-adult uses has no verified exact-stack controlled benefit-harm comparison. Short CJC tolerability, ipamorelin ileus monitoring, GH-axis metabolic risks and sampled product-identity problems cannot be combined into a measured exact-stack net benefit or universal toxicity conclusion.

SC1 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Controlled human CJC-1295 and ipamorelin reports establish single-agent GH-axis activity. For the recovery mechanism, these are endocrine biomarkers; the exact combination has no verified human functional result in this search. The biomarker cap is applied to inference from target engagement to recovery, not a denial that pharmacodynamic stimulation occurred.

SC2 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Partial biological support comes from single-agent human pharmacodynamics and related repair experiments. No examined report directly demonstrates a positive functional recovery effect of the exact CJC-1295 plus ipamorelin combination in the registered population. Different hormones, molecules, disease indications and animal injuries do not cross its clinical Δ threshold.

SC3 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. The claim that component evidence establishes all marketed stack benefits remains an unsupported generalization. The new BPC-157/TB-500 four-arm rat study supplies a useful counterexample to automatic additivity, while its own positive single-agent mechanical result retains its rat scope. Approved or studied single-agent indications remain distinct.

SC4 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. A broad net-benefit claim across promoted healthy-adult uses has no verified exact-stack controlled benefit-harm comparison. Short CJC tolerability, ipamorelin ileus monitoring, GH-axis metabolic risks and sampled product-identity problems cannot be combined into a measured exact-stack net benefit or universal toxicity conclusion.

SC1 applied rubric adaptation (distinct from the unchanged literal criterion): Clinical recovery adaptation: retain the exact frozen rubric and caps; require positive controlled patient-relevant function or healing for the registered intervention/population. GH and IGF-I changes are target engagement only.

SC2 applied rubric adaptation (distinct from the unchanged literal criterion): Clinical recovery adaptation: retain the exact frozen rubric and caps; require positive controlled patient-relevant function or healing for the registered intervention/population. GH and IGF-I changes are target engagement only.

SC3 applied rubric adaptation (distinct from the unchanged literal criterion): Clinical recovery adaptation: retain the exact frozen rubric and caps; require positive controlled patient-relevant function or healing for the registered intervention/population. GH and IGF-I changes are target engagement only.

SC4 applied rubric adaptation (distinct from the unchanged literal criterion): Clinical recovery adaptation: retain the exact frozen rubric and caps; require positive controlled patient-relevant function or healing for the registered intervention/population. GH and IGF-I changes are target engagement only.

SC1 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Single-species or single-strain evidence” Triggered for individual rat/mouse/rabbit repair-support inferences; ceiling Γ for transfer to the registered human stack. Separate human comparator trials are not re-capped as animal evidence.

SC1 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Triggered for endocrine, tracer, mitochondrial and body-composition-only support offered as physical recovery. Studies with genuine functional endpoints retain their different intervention and indication scope.

SC2 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Single-species or single-strain evidence” Triggered for individual rat/mouse/rabbit repair-support inferences; ceiling Γ for transfer to the registered human stack. Separate human comparator trials are not re-capped as animal evidence.

SC2 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Triggered for endocrine, tracer, mitochondrial and body-composition-only support offered as physical recovery. Studies with genuine functional endpoints retain their different intervention and indication scope.

SC3 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Single-species or single-strain evidence” Triggered for individual rat/mouse/rabbit repair-support inferences; ceiling Γ for transfer to the registered human stack. Separate human comparator trials are not re-capped as animal evidence.

SC3 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Triggered for endocrine, tracer, mitochondrial and body-composition-only support offered as physical recovery. Studies with genuine functional endpoints retain their different intervention and indication scope.

SC4 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Single-species or single-strain evidence” Triggered for individual rat/mouse/rabbit repair-support inferences; ceiling Γ for transfer to the registered human stack. Separate human comparator trials are not re-capped as animal evidence.

SC4 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Triggered for endocrine, tracer, mitochondrial and body-composition-only support offered as physical recovery. Studies with genuine functional endpoints retain their different intervention and indication scope.

Upward threshold ladder

SC1 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. A preregistered exact-formulation placebo-controlled combination/component-dismantling clinical test with positive patient-relevant function or healing, adequate power and concurrent adverse-event assessment in the defined population.

SC2 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. A preregistered exact-formulation placebo-controlled combination/component-dismantling clinical test with positive patient-relevant function or healing, adequate power and concurrent adverse-event assessment in the defined population.

SC3 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. A preregistered exact-formulation placebo-controlled combination/component-dismantling clinical test with positive patient-relevant function or healing, adequate power and concurrent adverse-event assessment in the defined population.

SC4 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. A preregistered exact-formulation placebo-controlled combination/component-dismantling clinical test with positive patient-relevant function or healing, adequate power and concurrent adverse-event assessment in the defined population.

Upper ladder: Human receptor blockade, pharmacological comparators, controlled injury experiments and indication-specific clinical trials were considered. No same-scope human genetics, natural experiment, withdrawal/rechallenge or independent causal-class set establishes the exact combination recovery benefit. Multiple peptide trials do not become independent causal lines solely through different molecules or sponsors.

Independence: All selected reports carry study-unit identifiers. No nominal Γ claim or companion reaches Ζ, so no independent causal lines are claimed. Parent trial reports are grouped conservatively; neighboring clinical comparators cannot create convergence for an untested exact intervention.

Falsification and pitfalls

Confirmation by biomarker. GH/IGF-I, tracer synthesis and DXA lean mass are substituted for physical recovery.

Selective generalization. Deficiency replacement, postoperative care and animal injuries are extrapolated to nondeficient adult stacks.

Mechanism conflation. Full-length thymosin beta4, TB-500 products, CJC-1295 formulations and ghrelin agonists are treated as interchangeable.

Negative field-valid perturbation read as a crossed threshold. The human ipamorelin ileus null and GH tendon-bone negatives remain contrasts, not positive Δ crossings.

Replication confused with reproduction. CJC proteomics and ROMANA post hoc analyses are grouped with parent cohorts.

Scope fitted to the result. Post hoc ROMANA subgroup positives cannot replace the original whole-trial primary result.

Adversarial steelman: above, then below

One rung above (Δ): single-agent GH-axis activation is direct, a receptor-blockade experiment implicates physiological GH in exercise capacity, and selected controlled GH or capromorelin trials improve function. That makes a combination recovery effect scientifically possible and supplies a strong rationale for a direct trial. The blinded recreational-athlete GH trial PMID20439575 also shows a genuine short-lived sprint-capacity benefit, making a blanket denial of performance effects untenable.

One rung below (Β): direct exact-combination human recovery is absent, and marketing may only associate exposure with subjective improvement or concurrent rehabilitation. If mechanistic evidence were merely co-occurrence, Β would follow.

Δ is rejected because no positive controlled exact-combination recovery endpoint in the registered population was verified; hormone stimulation cannot cross the phenotype threshold. Β is rejected because human component pharmacodynamics and preclinical receptor/repair interventions supply more than co-occurrence, although they leave the human combination dependency unshown. Thus Γ remains the primary-subclaim level.

Final score, causal direction and M/S/D

The preregistered primary-subclaim rule returns SC2 Γ: mechanistic plausibility and partial system support are present, but an exact-combination positive clinical recovery experiment is missing. This is an unproven benefit claim, not a claim that every peptide is ineffective or that future recovery benefit is impossible. Fifty-plus examined originals are mostly component, mechanism, comparator and indication-boundary reports, not fifty trials of the marketed combination.

For the registered combination and physical recovery, no causal dependency has been demonstrated in either direction. The required framework role is therefore epiphenomenon as an evidence-state classification, not proof that physiological GH or either component is biologically inactive. Endocrine perturbation is established separately.

Momentum: Mechanistic only. CJC-1295 human endocrine/proteomic experiments, ipamorelin preclinical-to-ileus work, and the 2026 BPC-157/TB-500 rat Achilles experiment are verified adjacent mechanistic or scoped work. No verified active exact-combination clinical recovery programme was identified in this bounded search.

Stability: Stable. A registered, formulation-verified, blinded exact-combination recovery trial could raise the score; none was verified as underway. No named pending result currently supplies a directional trigger.

Divergence: Contested. No manufactured field consensus or arithmetic gap. Artifact for the split: clinic and vendor framing of the exact stack as an established recovery aid implies a high rung, while the trial literature actually examined here contains no exact-combination functional test at all and several same-axis functional nulls, implying the bottom of the ladder for that claim (PMID18981485,25331030,1550219,7864103). These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

A preregistered blinded factorial comparison of formulation-verified CJC-1295, ipamorelin, their exact combination and placebo in a predefined adult recovery setting without diagnosed GH deficiency, with matched rehabilitation and an independently assessed functional recovery endpoint over 4–24 weeks.

Readout: A prespecified clinically meaningful return-to-activity or validated physical-function endpoint; hormone, body-water and mass outcomes secondary; adverse events and glycemic change analyzed alongside benefit. Controls: Exact molecular identity and batch verification, matched placebo and rehabilitation, component arms, blinded assessors, baseline injury/health eligibility, intention-to-treat analysis and prespecified clinically important effect. Supporting: The combination improves the prespecified functional endpoint beyond placebo with a credible benefit-harm balance; component arms identify whether additivity or a single component explains the result. Falsifying: Confirmed target engagement with no clinically meaningful function or healing advantage at adequate precision, or harms that outweigh the measured benefit; avoid interpreting underpowered nonsignificance as equivalence.

KNOWLEDGE GAPS

Direct human functional outcomes for the exact combination.

Formulation equivalence between long-acting albumin-binding CJC-1295 and products sold under similar names.

Component-dismantling evidence and patient-relevant synergy rather than hormone synergy.

Adequately powered functional endpoints and distinction between contractile tissue, fluid, appetite and measured recovery.

Longer-term controlled safety and net benefit under verified product exposure.

Translation of full-length thymosin beta4 and newer TB-500 animal mechanical results to defined human indications without treating different peptides as one class.

REVIEWER NOTES

Original complete abstracts/status records and selected Methods/Results were examined and receipted. No complete-paper or supplement audit, systematic-review exhaustiveness, blind calibration, independent scientific peer review or rendered video is claimed. Consensus generated output remains private; authored reconciliation is distinct.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

Consensus and original-source reconciliation

Consensus correctly identified two blinded placebo-controlled ascending-dose trials and GH/IGF-I outcomes. Its own grounding snippets are labeled Abstract, despite a broader claim of Methods/Results validation. The original abstract confirms hormone activity and short tolerability, not clinical recovery; no original full-body access is asserted for this paper. Original PMID16352683.

Consensus correctly reports a primary-null postoperative-ileus trial. The original randomized report gives meal-tolerance medians of 25.3 and 32.6 hours with p=0.15 and no significant key or secondary efficacy differences. This tests intravenous single-agent postoperative care, not the healthy-adult CJC-ipamorelin stack. Nonsignificance is not equivalence. Original PMID25331030.

Original Methods explicitly identify eleven men as a subset of a previously described cohort and repeat prior GH/IGF-I measurement procedures. The later serum-proteomic Results add candidate markers and correlations, not an independent clinical recovery experiment. Counts therefore group this report with the CJC pulsatility cohort rather than treating it as a new causal line. Original PMID19386527.

The original MK-677 Methods define blinded randomized treatment and function tests including walking, stairs and chair rise, with primary power for fat-free mass and visceral fat. Original Results show GH/IGF-I and mass changes, no significant function change, and worsened glycemic measures. This independently strengthens the provider-described biomarker/function boundary while retaining the limitation that functional nulls were not adequately powered equivalence tests. Original PMID18981485.

Consensus used this trial as a rigorous indication-specific comparator. Original Methods verify HIV-related abdominal adiposity enrollment, blinded treatment, CT/MRS and metabolic monitoring; Results confirm visceral/liver-fat reduction and transient glucose or insulin-sensitivity signals. These endpoints do not demonstrate healthy-adult recovery or establish the net benefit of another secretagogue combination. Original PMID25038357.

The provider summary relies heavily on reviews for healing-peptide boundaries. The examined 2026 original adds a four-arm thirty-two-rat Achilles-repair experiment: TB-500 alone showed significant mechanical benefit, and BPC-157 plus TB-500 did not add benefit over components. It strengthens the need for direct combination testing while preserving species, surgical-model and molecular-identity limits; it does not test CJC-ipamorelin. Original PMID42542926.

Consensus highlights the DAC versus similarly named marketed formulation boundary. The original analytical report identifies a twenty-nine-amino-acid peptide in an unknown product marketed as CJC-1295. Identity in that sample does not establish equivalence to the albumin-binding clinical formulation or market-wide safety and purity. Original PMID21204297.

Original human dose-escalation PK/PD confirms a GH episode after intravenous ipamorelin. This supports the biological rationale retained in the review, but it is neither an injected-combination clinical efficacy trial nor a chronic recovery-safety test. Provider included counts and research-gap matrix cells are not used as numbers of direct human efficacy trials. Original PMID10496658.

Consensus correctly notes a short-lived sprint effect and extracellular-water-driven lean-mass gain. The original blinded 96-athlete trial reports a 3.9 percent GH-associated sprint increase, no significant other performance changes and loss of the sprint effect after washout. This positive is retained rather than cherry-picking only null GH comparators; it is a different hormone exposure and endpoint from exact-stack recovery. Original PMID20439575.

The original two randomized high-dose GH trials show increased mortality in prolonged critical illness. This serious harm must remain bounded to its measured population and exposure; it cannot become an asserted CJC-ipamorelin mortality rate in healthy adults. Original PMID10477776.

Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.

Research timeline and gaps: Injectable Peptide Stacks and Human Recovery

Selected publication milestones, not an exhaustive history or discovery priority claim.

1991 — Local GH can change acute forearm protein kinetics; this establishes physiology, not lasting recovery. Original PMID2003602.

1992 — GH-plus-training trial in young men adds mass and whole-body synthesis without extra muscle-strength benefit. Original PMID1550219.

1994 — Long-term GH-deficiency replacement illustrates a separate baseline-deficiency indication. Original PMID8156094.

1995 — Older-adult matched-training comparison shows additional GH mass/water change without added strength. Original PMID7864103.

1997 — Older-adult GHRH before-after findings combine selected functional changes with null metabolic and composition measures; controls remain limited. Original PMID9005976.

1998 — Ipamorelin receptor profiling and animal hormone selectivity establish a mechanistic starting point. Original PMID9849822.

1999 — Human ipamorelin pharmacodynamics show GH stimulation without physical recovery endpoints. Original PMID10496658.

1999 — Two critically ill adult trials demonstrate high-dose GH mortality harm in a distinct severe clinical context. Original PMID10477776.

2001 — Mouse secretagogue adiposity effects challenge assuming all actions are explained by GH. Original PMID11162489.

2002 — Older-adult factorial GH/sex-steroid study shows sex- and endpoint-specific findings alongside adverse effects. Original PMID12425705.

2003 — Controlled perioperative GH produces selected walking and muscle-preservation benefit with frequent dose-related side effects. Original PMID12519419.

2006 — Blinded CJC-1295 ascending-dose human trials demonstrate prolonged GH/IGF-I activity. Original PMID16352683.

2006 — CJC pulsatility measurements refine endocrine engagement without adding a clinical recovery trial. Original PMID17018654.

2008 — MK-677 increases hormones and fat-free mass while measured function remains unchanged; glycemic monitoring supplies a safety boundary. Original PMID18981485.

2009 — A CJC cohort subset adds serum-proteomic markers, not independent functional replication. Original PMID19386527.

2009 — Capromorelin shows selected older-adult functional outcomes in a different drug and predefined limitation setting. Original PMID19174493.

2010 — A blinded athlete study retains a real sprint positive, with null other performance endpoints and loss after washout. Original PMID20439575.

2013 — GH rat tendon-bone repair is null in one protocol and mechanically worse in prolonged high-dose exposure. Original PMID23636184.

2014 — Human postoperative ipamorelin does not improve its key meal-tolerance endpoint despite rodent motility support. Original PMID25331030.

2014 Jul 23-30 — Tesamorelin improves adiposity endpoints in HIV-related disease with explicit metabolic monitoring. Original PMID25038357.

2016 — Two ROMANA trials show lean-mass gains without co-primary handgrip improvement in cancer cachexia. Original PMID26906526.

2026 — A recent BPC-157/TB-500 rat component comparison finds no added combination benefit, reinforcing molecule-specific testing. Original PMID42542926.

Research gaps

Direct human functional outcomes for the exact combination.

Formulation equivalence between long-acting albumin-binding CJC-1295 and products sold under similar names.

Component-dismantling evidence and patient-relevant synergy rather than hormone synergy.

Adequately powered functional endpoints and distinction between contractile tissue, fluid, appetite and measured recovery.

Longer-term controlled safety and net benefit under verified product exposure.

Translation of full-length thymosin beta4 and newer TB-500 animal mechanical results to defined human indications without treating different peptides as one class.

Boundary experiment

A preregistered blinded factorial comparison of formulation-verified CJC-1295, ipamorelin, their exact combination and placebo in a predefined adult recovery setting without diagnosed GH deficiency, with matched rehabilitation and an independently assessed functional recovery endpoint over 4–24 weeks.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14 (Round 2, group 12). Scope of checks: 56/56 reference PMIDs verified against PubMed metadata (0 failed, 0 retractions or expressions of concern); 13 load-bearing claims spot-checked, with particular attention to the safety and efficacy attributions, since the subject is an unapproved consumer product; scoring logic re-derived against hsef-framework.md and the v5.3 SKILL (universal and rubric caps, pre-registered primary-subclaim aggregation, role derivation, upward ladder, M/S/D artifacts); the known upstream defects screened.

Rejected findings (checked, no change)

1. Level and aggregation. Primary-subclaim is pre-registered and applied as written: SC2 is the designated primary subclaim, it is the one that carries the registered clinical proposition, and its Γ sets the headline while SC1, SC3 and SC4 are reported without gating. All three alternatives are reported (weakest-link Α, primary-subclaim Γ, scope-matched Γ). Δ rejected: no positive controlled functional or healing endpoint for the exact combination in the registered population was verified, and endocrine engagement cannot cross a phenotype threshold. Β rejected: human component pharmacodynamics and preclinical receptor-blockade and repair interventions supply more than co-occurrence.
2. "Best-supported rival" renderer bug. Checked and absent. The score card marks models_evaluated[0] as is_nominal: false, rank 1, so the printed rival (Indication-specific single-agent effects do not transfer to stacks, Ε) is genuinely the highest-ranked non-nominal model; the nominal is rank 4.
3. Causal role. epiphenomenon is correct by the derivation procedure, which reaches it at step 2 (no demonstrated causal dependency in either direction for the registered combination and recovery outcome). The review states explicitly that this is an evidence-state classification and not a claim that GH or either component is biologically inactive, which is the honest reading.
4. Momentum. "Mechanistic only" is correct and the artifact names the work (CJC-1295 endocrine and proteomic experiments, ipamorelin preclinical-to-ileus development, the 2026 BPC-157/TB-500 rat Achilles experiment). No upgrade to "Decisive work underway" is available because no exact-combination clinical programme was identified.
5. Safety and efficacy attribution (the point of special concern for an unapproved consumer product). Verified accurate in both directions and neither overstated nor understated. The high-dose growth-hormone mortality result is correctly reported (two parallel randomized trials, 247 Finnish plus 285 other European patients, 39 versus 20 percent and 44 versus 18 percent in-hospital mortality) and is explicitly bounded to prolonged critical illness rather than converted into a stack death rate; the review states on its own initiative that no unverified CJC-associated death allegation is used. Harms are not inflated: the rat tendon-bone finding is held to its animal model and high dose, and the product-identity report is held to one sampled product rather than market-wide impurity. Benefits are not understated either: the genuine positives are retained rather than filtered out, including the blinded 96-athlete 3.9 percent sprint gain with its loss after washout, perioperative growth hormone improving four-minute walking distance in 33 hip-replacement patients, and capromorelin improving tandem walk and stair climb in 395 older adults with mild functional limitation. The net-benefit subclaim is held at Α in both directions: no measured exact-stack benefit-harm comparison and no universal toxicity conclusion.
6. Numeric claims. Verified against PubMed abstracts: ipamorelin ileus 117 enrolled with meal-tolerance medians 25.3 and 32.6 hours at p=0.15; MK-677 65 participants; ROMANA 1 and 2 totalling 979 with co-primary lean body mass and handgrip strength; Blackman factorial 131 (57 women, 74 men) over 26 weeks; growth-hormone receptor antagonist in 20 healthy men; the four-arm Achilles study with 32 rats in groups of eight, significant only for TB-500 alone; CJC-1295 identified as a twenty-nine-amino-acid peptide in one unknown marketed product.
7. Citation years. References 1 (2005/2006), 16 (2013/2014), 22 (2006/2007), 24 (2007/2008) and 45 (2010/2011) differ from the PubMed e-pub year by one. Rejected per convention.
8. Collective-author defect, "PMIDnot supplied", false approval boilerplate, REVIEWER NOTES contradiction. Screened; none present. This package is not one of the 9 October revised editions, so the spliced provenance clauses do not arise, and its own Consensus reconciliation section is internally consistent with REVIEWER NOTES (Consensus used for discovery and cross-checking, provider output not treated as original full text).
9. Rubric routing. Routing a sports-recovery claim to the metabolism and aging rubric is a declared adaptation, the literal frozen criteria are printed unchanged alongside it, and the adaptation is stated not to convert a null or a different molecule into a positive crossing. This is the framework-sanctioned way to handle a missing rubric and was not rewritten.

Residual limitations

Only three originals were read at partial-body depth (tesamorelin, MK-677 and the CJC proteomic subset), so Methods-level figures elsewhere rest on abstracts and status records, as the review states. The same fused-token rendering defects corrected here also appear in the sibling case artifacts (CONSENSUS_CROSSCHECK.md, RESEARCH_TIMELINE.md, research-timeline.json, evidence.json, adjudication.json, adjudication-draft.json, enrichment-draft.json, consensus-validation.json); the string pairs are listed in ADVERSARIAL_REVIEW.md for the lead. The review does not state in terms that neither CJC-1295 nor ipamorelin is an approved medicine for any indication; this was checked and is not an error, since no approval is asserted anywhere and the approved comparator (tesamorelin) is correctly confined to its HIV indication, but a reader-facing edition would benefit from saying so plainly.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

REFERENCES

1. Teichman SL, Neale A, Lawrence B et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism. 2006. PMID 16352683. DOI: 10.1210/jc.2005-1536. Access: abstract_metadata. Study: PMID16352683.

2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism. 2006. PMID 17018654. DOI: 10.1210/jc.2006-1702. Access: abstract_metadata. Study: CJC-pulsatility-cohort.

3. Beck DE, Sweeney WB, McCarter MD et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease. 2014. PMID 25331030. DOI: 10.1007/s00384-014-2030-8. Access: abstract_metadata. Study: PMID25331030.

4. Gobburu JV, Agersø H, Jusko WJ et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical research. 1999. PMID 10496658. DOI: 10.1023/a:1018955126402. Access: abstract_metadata. Study: PMID10496658.

5. Brady RD, Grills BL, Schuijers JA et al. Thymosin β4 administration enhances fracture healing in mice. Journal of orthopaedic research : official publication of the Orthopaedic Research Society. 2014. PMID 25042765. DOI: 10.1002/jor.22686. Access: abstract_metadata. Study: PMID25042765.

6. Guarnera G, DeRosa A, Camerini R et al. The effect of thymosin treatment of venous ulcers. Annals of the New York Academy of Sciences. 2010. PMID 20536470. DOI: 10.1111/j.1749-6632.2010.05490.x. Access: abstract_metadata. Study: PMID20536470.

7. Ehrlich HP, Hazard SW. Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts. Annals of the New York Academy of Sciences. 2010. PMID 20536458. DOI: 10.1111/j.1749-6632.2010.05483.x. Access: abstract_metadata. Study: PMID20536458.

8. Li Y, Wang G, Yu H et al. [Expression of laminin 5 in rat skin wounds regulated by recombinant thymosin beta4]. Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery. 2008. PMID 19068595. DOI: not available. Access: abstract_metadata. Study: PMID19068595.

9. White HK, Petrie CD, Landschulz W et al. Effects of an oral growth hormone secretagogue in older adults. The Journal of clinical endocrinology and metabolism. 2009. PMID 19174493. DOI: 10.1210/jc.2008-0632. Access: abstract_metadata. Study: PMID19174493.

10. Brill KT, Weltman AL, Gentili A et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. The Journal of clinical endocrinology and metabolism. 2002. PMID 12466367. DOI: 10.1210/jc.2002-020098. Access: abstract_metadata. Study: PMID12466367.

11. Jørgensen JO, Thuesen L, Müller J et al. Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance. European journal of endocrinology. 1994. PMID 8156094. DOI: 10.1530/eje.0.1300224. Access: abstract_metadata. Study: PMID8156094.

12. González-Sales M, Barrière O, Tremblay PO et al. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clinical pharmacokinetics. 2015. PMID 25358450. DOI: 10.1007/s40262-014-0202-x. Access: abstract_metadata. Study: PMID25358450.

13. Falutz J, Allas S, Kotler D et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS (London, England). 2005. PMID 16052083. DOI: 10.1097/01.aids.0000180099.35146.30. Access: abstract_metadata. Study: PMID16052083.

14. Stanley TL, Feldpausch MN, Oh J et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014 Jul 23-30. PMID 25038357. DOI: 10.1001/jama.2014.8334. Access: full_text_partial. Study: NCT01263717.

15. Braun LR, Feldpausch MN, Czerwonka N et al. Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2017. PMID 29031905. DOI: 10.1016/j.ghir.2017.10.002. Access: abstract_metadata. Study: NCT01263717.

16. Nellemann B, Vendelbo MH, Nielsen TS et al. Growth hormone-induced insulin resistance in human subjects involves reduced pyruvate dehydrogenase activity. Acta physiologica (Oxford, England). 2014. PMID 24148194. DOI: 10.1111/apha.12183. Access: abstract_metadata. Study: PMID24148194.

17. Høgild ML, Hjelholt AJ, Hansen J et al. Ketone Body Infusion Abrogates Growth Hormone-Induced Lipolysis and Insulin Resistance. The Journal of clinical endocrinology and metabolism. 2023. PMID 36240323. DOI: 10.1210/clinem/dgac595. Access: abstract_metadata. Study: PMID36240323.

18. Goto K, Doessing S, Nielsen RH et al. Growth hormone receptor antagonist treatment reduces exercise performance in young males. The Journal of clinical endocrinology and metabolism. 2009. PMID 19549743. DOI: 10.1210/jc.2009-0407. Access: abstract_metadata. Study: PMID19549743.

19. Fryburg DA, Gelfand RA, Barrett EJ. Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans. The American journal of physiology. 1991. PMID 2003602. DOI: 10.1152/ajpendo.1991.260.3.E499. Access: abstract_metadata. Study: PMID2003602.

20. Vittone J, Blackman MR, Busby-Whitehead J et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism: clinical and experimental. 1997. PMID 9005976. DOI: 10.1016/s0026-0495(97)90174-8. Access: abstract_metadata. Study: PMID9005976.

21. Weissberger AJ, Anastasiadis AD, Sturgess I et al. Recombinant human growth hormone treatment in elderly patients undergoing elective total hip replacement. Clinical endocrinology. 2003. PMID 12519419. DOI: 10.1046/j.1365-2265.2003.01700.x. Access: abstract_metadata. Study: PMID12519419.

22. Krag MB, Gormsen LC, Guo Z et al. Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics. American journal of physiology. Endocrinology and metabolism. 2007. PMID 17132823. DOI: 10.1152/ajpendo.00374.2006. Access: abstract_metadata. Study: PMID17132823.

23. Esposito JG, Thomas SG, Kingdon L et al. Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial. The Journal of clinical endocrinology and metabolism. 2004. PMID 15472216. DOI: 10.1210/jc.2004-0451. Access: abstract_metadata. Study: PMID15472216.

24. Short KR, Moller N, Bigelow ML et al. Enhancement of muscle mitochondrial function by growth hormone. The Journal of clinical endocrinology and metabolism. 2008. PMID 18000087. DOI: 10.1210/jc.2007-1814. Access: abstract_metadata. Study: PMID18000087.

25. Murphy MG, Plunkett LM, Gertz BJ et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism. 1998. PMID 9467534. DOI: 10.1210/jcem.83.2.4551. Access: abstract_metadata. Study: PMID9467534.

26. Temel JS, Abernethy AP, Currow DC et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. The Lancet. Oncology. 2016. PMID 26906526. DOI: 10.1016/S1470-2045(15)00558-6. Access: abstract_metadata. Study: ROMANA1-and-ROMANA2.

27. Yamamoto K, Kurokawa Y, Miyazaki Y et al. Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial. EClinicalMedicine. 2025. PMID 41181834. DOI: 10.1016/j.eclinm.2025.103500. Access: abstract_metadata. Study: PMID41181834.

28. Krug O, Thomas A, Malerød-Fjeld H et al. Analysis of new growth promoting black market products. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2018. PMID 29864719. DOI: 10.1016/j.ghir.2018.05.001. Access: abstract_metadata. Study: PMID29864719.

29. Laird BJA, Skipworth R, Bonomi PD et al. Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2. Journal of cachexia, sarcopenia and muscle. 2025. PMID 39992021. DOI: 10.1002/jcsm.13732. Access: abstract_metadata. Study: ROMANA1-and-ROMANA2.

30. Blum RA, Mair S, Duus EM. Appetite and food intake results from phase I studies of anamorelin. Journal of cachexia, sarcopenia and muscle. 2019. PMID 31074178. DOI: 10.1002/jcsm.12439. Access: abstract_metadata. Study: PMID31074178.

31. Sigalos JT, Pastuszak AW, Allison A et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. American journal of men's health. 2017. PMID 28830317. DOI: 10.1177/1557988317718662. Access: abstract_metadata. Study: PMID28830317.

32. Raun K, Hansen BS, Johansen NL et al. Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology. 1998. PMID 9849822. DOI: 10.1530/eje.0.1390552. Access: abstract_metadata. Study: PMID9849822.

33. Johansen PB, Nowak J, Skjaerbaek C et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 1999. PMID 10373343. DOI: 10.1054/ghir.1999.9998. Access: abstract_metadata. Study: PMID10373343.

34. Sackmann-Sala L, Ding J, Frohman LA et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2009. PMID 19386527. DOI: 10.1016/j.ghir.2009.03.001. Access: full_text_partial. Study: CJC-pulsatility-cohort.

35. Lall S, Tung LY, Ohlsson C et al. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and biophysical research communications. 2001. PMID 11162489. DOI: 10.1006/bbrc.2000.4065. Access: abstract_metadata. Study: PMID11162489.

36. Venkova K, Mann W, Nelson R et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. The Journal of pharmacology and experimental therapeutics. 2009. PMID 19289567. DOI: 10.1124/jpet.108.149211. Access: abstract_metadata. Study: PMID19289567.

37. Henninge J, Pepaj M, Hullstein I et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis. 2010. PMID 21204297. DOI: 10.1002/dta.233. Access: abstract_metadata. Study: PMID21204297.

38. Greenwood-Van Meerveld B, Tyler K, Mohammadi E et al. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology. 2012. PMID 27186127. DOI: 10.2147/JEP.S35396. Access: abstract_metadata. Study: PMID27186127.

39. Corrick RM, Li L, Frank SJ et al. Hepatic growth hormone resistance after acute injury. Endocrinology. 2013. PMID 23417424. DOI: 10.1210/en.2012-2134. Access: abstract_metadata. Study: PMID23417424.

40. Fernández-Mayola M, Betancourt L, Molina-Kautzman A et al. Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study. International wound journal. 2018. PMID 29464859. DOI: 10.1111/iwj.12895. Access: abstract_metadata. Study: PMID29464859.

41. Ramirez RJ, Wolf SE, Barrow RE et al. Growth hormone treatment in pediatric burns: a safe therapeutic approach. Annals of surgery. 1998. PMID 9790334. DOI: 10.1097/00000658-199810000-00001. Access: abstract_metadata. Study: PMID9790334.

42. Messias de Lima CF, de Araújo Vieira LF, de Carvalho Wanderley LA et al. Topical Growth Hormone Accelerates Wound Healing in Mice. Wounds : a compendium of clinical research and practice. 2017. PMID 28976342. DOI: not available. Access: abstract_metadata. Study: PMID28976342.

43. Singh KP, Prasad R, Chari PS et al. Effect of growth hormone therapy in burn patients on conservative treatment. Burns : journal of the International Society for Burn Injuries. 1998. PMID 9915674. DOI: 10.1016/s0305-4179(98)00113-2. Access: abstract_metadata. Study: PMID9915674.

44. Baumgarten KM, Oliver HA, Foley J et al. Human growth hormone may be detrimental when used to accelerate recovery from acute tendon-bone interface injuries. The Journal of bone and joint surgery. American volume. 2013. PMID 23636184. DOI: 10.2106/JBJS.L.00222. Access: abstract_metadata. Study: PMID23636184.

45. Tokura Y, Nakayama Y, Fukada S et al. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. Journal of biochemistry. 2011. PMID 20880960. DOI: 10.1093/jb/mvq115. Access: abstract_metadata. Study: PMID20880960.

46. Biçer O, Adanir O, Güleryüz Y et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery. 2026. PMID 42542926. DOI: 10.52312/jdrs.2026.2951. Access: abstract_metadata. Study: PMID42542926.

47. Malinda KM, Sidhu GS, Mani H et al. Thymosin beta4 accelerates wound healing. The Journal of investigative dermatology. 1999. PMID 10469335. DOI: 10.1046/j.1523-1747.1999.00708.x. Access: abstract_metadata. Study: PMID10469335.

48. Xu B, Yang M, Li Z et al. Thymosin β4 enhances the healing of medial collateral ligament injury in rat. Regulatory peptides. 2013. PMID 23523891. DOI: 10.1016/j.regpep.2013.03.026. Access: abstract_metadata. Study: PMID23523891.

49. Zhu T, Park HC, Son KM et al. Effects of thymosin β4 on wound healing of rat palatal mucosa. International journal of molecular medicine. 2014. PMID 24993983. DOI: 10.3892/ijmm.2014.1832. Access: abstract_metadata. Study: PMID24993983.

50. Li X, Zheng L, Peng F et al. Recombinant thymosin beta 4 can promote full-thickness cutaneous wound healing. Protein expression and purification. 2007. PMID 17923415. DOI: 10.1016/j.pep.2007.08.011. Access: abstract_metadata. Study: PMID17923415.

51. Nass R, Pezzoli SS, Oliveri MC et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of internal medicine. 2008. PMID 18981485. DOI: 10.7326/0003-4819-149-9-200811040-00003. Access: full_text_partial. Study: PMID18981485.

52. Meinhardt U, Nelson AE, Hansen JL et al. The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial. Annals of internal medicine. 2010. PMID 20439575. DOI: 10.7326/0003-4819-152-9-201005040-00007. Access: abstract_metadata. Study: PMID20439575.

53. Yarasheski KE, Campbell JA, Smith K et al. Effect of growth hormone and resistance exercise on muscle growth in young men. The American journal of physiology. 1992. PMID 1550219. DOI: 10.1152/ajpendo.1992.262.3.E261. Access: abstract_metadata. Study: PMID1550219.

54. Yarasheski KE, Zachwieja JJ, Campbell JA et al. Effect of growth hormone and resistance exercise on muscle growth and strength in older men. The American journal of physiology. 1995. PMID 7864103. DOI: 10.1152/ajpendo.1995.268.2.E268. Access: abstract_metadata. Study: PMID7864103.

55. Takala J, Ruokonen E, Webster NR et al. Increased mortality associated with growth hormone treatment in critically ill adults. The New England journal of medicine. 1999. PMID 10477776. DOI: 10.1056/NEJM199909093411102. Access: abstract_metadata. Study: PMID10477776.

56. Blackman MR, Sorkin JD, Münzer T et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002. PMID 12425705. DOI: 10.1001/jama.288.18.2282. Access: abstract_metadata. Study: PMID12425705.

Source-specific evidence cards

[1] Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

Shows: CJC-1295 alone increased GH and IGF-I for days in two placebo-controlled ascending-dose trials in healthy adults; no serious adverse reactions were reported over 28-49 days.

Does not show: No combined ipamorelin arm or functional recovery endpoint was measured; short monitored tolerability does not establish chronic stack benefit or safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[2] Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

Shows: CJC-1295 in healthy men increased trough and mean GH and IGF-I while preserving pulsatility after one week.

Does not show: Endocrine dynamics are target engagement rather than recovery; no exact combination or functional comparison was tested.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[3] Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.

Shows: A blinded placebo-controlled phase 2 intravenous ipamorelin study randomized 117 bowel-resection patients; the key meal-tolerance endpoint and secondary efficacy analyses showed no significant differences.

Does not show: Postoperative ileus, intravenous single-agent dosing and seven-day exposure differ from healthy-adult injectable stacks; nonsignificance does not prove exact equality or refute all doses.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

[4] Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.

Shows: Dose-escalation intravenous ipamorelin in healthy male volunteers produced a single GH episode and supported a pharmacokinetic-pharmacodynamic model.

Does not show: A hormone response and modeled potency do not show physical recovery, combination efficacy or chronic subcutaneous safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[5] Thymosin β4 administration enhances fracture healing in mice.

Shows: Intraperitoneal full-length thymosin beta 4 increased fracture-callus force to failure and stiffness after fibular osteotomy in mice.

Does not show: This is another molecule in one injury model and species; TB-500 product equivalence and CJC-ipamorelin recovery are not established.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[6] The effect of thymosin treatment of venous ulcers.

Shows: A blinded dose-escalation trial randomized 73 venous-ulcer patients to topical full-length thymosin beta 4 or placebo; abstract findings suggest wound-healing potential at 0.03 percent and acceptable short-term tolerability.

Does not show: The abstract does not supply a decisive between-arm efficacy contrast; compression care, formulation, indication and topical route block inference to healthy-adult peptide stacks.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[7] Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts.

Shows: Local thymosin beta 4 in rat incisions improved collagen organization and wound narrowing without loss of breaking strength.

Does not show: Histological organization and local rat repair do not establish injected TB-500 or combined human secretagogue recovery.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[8] [Expression of laminin 5 in rat skin wounds regulated by recombinant thymosin beta4].

Shows: Topical recombinant thymosin beta 4 in 60 rats changed laminin 5 expression and accelerated full-thickness wound closure at selected doses and times.

Does not show: Wound contractions, model, route and dose-specific effects constrain translation; the marketed exact combination was absent.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[9] Effects of an oral growth hormone secretagogue in older adults.

Shows: Capromorelin in 395 older adults with mild functional limitation increased IGF-I and lean mass; pooled active groups improved tandem walk at six months and stair climb at 12 months, with glycemic and other adverse signals.

Does not show: The trial stopped early under predefined effect criteria; pooled outcomes, another oral molecule, baseline limitation and longer horizon do not validate healthy-adult CJC-ipamorelin stacks.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

[10] Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men.

Shows: A randomized-order 10-man hormone crossover study found selected balance, walking and stair changes, increased fat-free mass with combined GH plus testosterone, and no strength or flexibility change.

Does not show: Comparisons against baseline, short exposure, small sample and different hormone combination limit placebo-controlled stack inference; mass and muscle gene expression are not uniform functional recovery.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

[11] Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance.

Shows: A three-year open continuation in 10 GH-deficient adults maintained improved muscle volume and improved exercise capacity and strength compared with the original placebo period.

Does not show: Replacement of diagnosed deficiency lies outside the registered population; the uncontrolled continuation cannot establish healthy-adult stack enhancement.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

[12] Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.

Shows: A 38-person tesamorelin analysis characterized repeated-dose pharmacokinetics in healthy subjects and HIV-infected patients.

Does not show: Pharmacokinetic modeling of another GHRH analogue is not physical recovery, component synergy or clinical safety evidence for the exact stack.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[13] A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.

Shows: A 61-person blinded TH 9507 trial in HIV-related central adiposity raised IGF-I, reduced trunk fat at the higher dose and improved selected lipid measures; visceral-fat reduction was not significant.

Does not show: Indication-specific adiposity and metabolic endpoints of another molecule do not establish physical recovery or universal stack net benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[14] Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Shows: Tesamorelin in 50 HIV-infected adults with abdominal fat reduced visceral and liver fat versus placebo over six months; transient fasting-glucose increase was observed at two weeks.

Does not show: Different molecule and indication; adiposity endpoints and transient glycemic changes do not establish CJC-ipamorelin functional recovery or clinical net benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph2, 1:Methods:paragraph4, 1:Methods:paragraph6, 2:Results:paragraph3, 2:Results:paragraph4, 2:Results:paragraph5, 2:Results:paragraph12. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[15] Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.

Shows: A secondary analysis of the 50-person tesamorelin liver-fat trial associated falling FGF 21 with liver-fat and biochemical changes; the treatment contrast for FGF 21 was only a trend.

Does not show: Same-study secondary associations do not identify mediation or add an independent trial; liver-fat indication is outside healthy-adult recovery.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[16] Growth hormone-induced insulin resistance in human subjects involves reduced pyruvate dehydrogenase activity.

Shows: Randomized GH infusion in eight healthy men promoted lipolysis and reduced clamp insulin sensitivity by approximately half, with reduced active pyruvate dehydrogenase.

Does not show: Acute pharmacological GH infusion establishes a metabolic risk mechanism, not the chronic adverse-event rate of an untested secretagogue combination.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[17] Ketone Body Infusion Abrogates Growth Hormone-Induced Lipolysis and Insulin Resistance.

Shows: In eight healthy men receiving GH infusion, ketone infusion suppressed free fatty acids and improved glucose disposal compared with saline.

Does not show: This mechanistic rescue suggests context dependence of GH-related insulin resistance; it does not establish a safe clinical peptide stack or recovery benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[18] Growth hormone receptor antagonist treatment reduces exercise performance in young males.

Shows: A placebo-controlled GH-receptor antagonist trial in twenty healthy men shortened prolonged-exercise time to exhaustion without changing VO2 max.

Does not show: Physiological GH contribution under receptor blockade does not prove benefit from supraphysiological stimulation or the exact peptide combination.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[19] Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans.

Shows: Local GH infusion in seven healthy men increased forearm amino-acid uptake consistent with acute muscle protein synthesis.

Does not show: A short regional tracer response does not demonstrate stronger muscle, healing or lasting physical recovery.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[20] Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.

Shows: Six-week nightly GHRH treatment in eleven older men increased GH and selected strength/endurance measures but not IGF-I, body composition or muscle-energy measures.

Does not show: An uncontrolled before-after study of another formulation is vulnerable to practice effects and multiple outcomes; it cannot establish placebo-controlled stack benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[21] Recombinant human growth hormone treatment in elderly patients undergoing elective total hip replacement.

Shows: Blinded GH versus placebo in thirty-three older hip-replacement patients improved postoperative four-minute walking distance and selected muscle preservation; most recipients had dose-related side effects.

Does not show: Perioperative GH and underlying osteoarthritis differ from healthy-adult secretagogue stacks; selective strength findings and small sample limit generalization.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

[22] Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics.

Shows: A nine-man blinded crossover trial found GH-induced insulin resistance, including with concomitant acipimox, and increased muscle triglyceride content.

Does not show: Physiological mechanism and pharmacological dose are relevant boundaries, not quantified chronic exact-stack harm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[23] Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial.

Shows: A twelve-person blinded crossover GH trial in HIV-associated wasting improved peripheral oxygen extraction during exercise.

Does not show: Disease wasting, recombinant GH and oxygen-extraction physiology cannot validate recovery enhancement in nondeficient healthy adults.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[24] Enhancement of muscle mitochondrial function by growth hormone.

Shows: A nine-person randomized GH-infusion crossover increased mitochondrial oxidative capacity and whole-body protein synthesis, with glucose, insulin and fatty-acid changes.

Does not show: Mitochondrial and tracer endpoints are biomarkers; there was no functional recovery measurement or exact combination.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[25] MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.

Shows: MK-677 in eight calorically restricted healthy adults improved nitrogen balance and GH/IGF-I over seven treatment days versus placebo.

Does not show: Diet-induced nitrogen wasting is a short metabolic endpoint, not strength or return to activity; another oral molecule cannot establish stack efficacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[26] Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.

Shows: The two ROMANA trials randomized 979 lung-cancer cachexia patients; anamorelin increased lean mass but did not improve co-primary handgrip strength, with some severe hyperglycemia.

Does not show: Cancer cachexia and a different oral ghrelin agonist are outside the nominal population; null handgrip is a mass-versus-function boundary rather than proof all axis stimulation fails.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

[27] Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial.

Shows: A 203-person open randomized gastric-cancer cachexia trial did not meet its primary between-arm lean-mass endpoint at eight weeks; hyperglycemia occurred in the active arm.

Does not show: Modified per-protocol analysis, no placebo blinding and another disease-specific drug constrain inference; a nonsignificant trend is not established benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

[28] Analysis of new growth promoting black market products.

Shows: Mass-spectrometric testing identified altered GH and glycine-extended GHRP-2, GHRP-6 and ipamorelin in black-market growth products, with synthetic confirmation of selected identities.

Does not show: Analytical identity evidence from sampled products cannot estimate market-wide adulteration prevalence or clinical efficacy and harms.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[29] Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2.

Shows: A post hoc ROMANA analysis of 795 patients associated greater clinical improvements with selected baseline inflammation and wasting groups, including subgroup handgrip findings.

Does not show: This is the same parent trials and post hoc subgroup analysis; it does not erase the null co-primary handgrip results or create a new independent functional trial.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[30] Appetite and food intake results from phase I studies of anamorelin.

Shows: Two small blinded healthy-adult phase 1 anamorelin studies increased hunger and, at selected doses, caloric intake.

Does not show: Appetite effects show a possible non-GH route to weight gain; they are not recovery, stack synergy or proof that increased mass means improved function.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3, SC4.

[31] Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.

Shows: A retrospectively selected fourteen-man testosterone-treated cohort receiving GHRP-2/GHRP-6/sermorelin showed increased IGF-I.

Does not show: Only fourteen of 105 met compliance criteria, co-treatments varied, and no credible control or physical outcome was measured; another triple combination does not validate CJC-ipamorelin.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[32] Ipamorelin, the first selective growth hormone secretagogue.

Shows: Ipamorelin stimulated GH in rat pituitary cells, rats and swine; antagonist profiling supported a GHRP-like receptor and comparatively selective hormonal effects in swine.

Does not show: Preclinical selectivity and acute GH release do not establish healthy-adult recovery or long-term combination safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[33] Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.

Shows: Ipamorelin increased longitudinal bone growth and body-weight gain over fifteen days in adult female rats, without measured total IGF-I change.

Does not show: Rat longitudinal growth is not adult human injury recovery; species, growth physiology and formulation boundaries remain.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[34] Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.

Shows: CJC-1295-associated serum proteomic changes in eleven healthy men supplied candidate markers of GH/IGF-I activity.

Does not show: Before-after protein spots and correlations do not measure recovery or isolate mediation; participant overlap with the parent CJC pulsatility work must be grouped.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:2. Materials and Methods:paragraph0, 1:2. Materials and Methods:paragraph1, 1:2. Materials and Methods:paragraph13, 2:3. Results:paragraph2, 2:3. Results:paragraph3, 2:3. Results:paragraph4. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[35] Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.

Shows: Ipamorelin increased adiposity and food intake in GH-intact and GH-deficient mice, indicating GH-independent actions differing from GH itself.

Does not show: Mouse adiposity does not establish a human harm rate; it challenges assuming every secretagogue effect is explained by the GH axis.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3, SC4.

[36] Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.

Shows: Intravenous ipamorelin improved selected bowel-transit and, with repeated dosing, output and intake measures in a rat postoperative-ileus model.

Does not show: Rodent gastrointestinal recovery did not translate to the primary human ipamorelin meal-tolerance result; healthy-adult muscular recovery was not tested.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[37] Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.

Shows: Mass spectrometry identified a twenty-nine-amino-acid peptide marketed as CJC-1295 in an unknown pharmaceutical preparation.

Does not show: A market label and a sequence are insufficient evidence of equivalence to the long-acting albumin-binding clinical formulation or of efficacy, purity and safety across products.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[38] Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.

Shows: Ipamorelin improved postoperative gastric emptying in rats and rescued contractile responses in isolated gastric tissue.

Does not show: Single-agent animal motility does not establish a healthy-adult stack or overcome the human ileus trial's null efficacy result.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[39] Hepatic growth hormone resistance after acute injury.

Shows: Mouse acute-injury and hemorrhage models showed rapidly impaired hepatic GH signaling and altered receptor features despite GH challenge.

Does not show: A signaling-resistance model does not establish clinical recovery benefit or justify increasing doses; injured physiology differs from healthy adults.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[40] Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study.

Shows: GHRP-6 prevented hypertrophic scarring in a rabbit model but did not significantly reverse established scars.

Does not show: Another peptide, local route and stage-specific injury model are not direct CJC-ipamorelin clinical evidence; early proteomics do not prove the causal mediator.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[41] Growth hormone treatment in pediatric burns: a safe therapeutic approach.

Shows: A pediatric severe-burn report combining randomized and matched comparisons found similar mortality but greater hyperglycemia and insulin requirements with GH.

Does not show: Retrospective aggregation, mixed controls and pediatric burn indication prevent extrapolating reported safety to critically ill adults or healthy-adult peptide stacks.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[42] Topical Growth Hormone Accelerates Wound Healing in Mice.

Shows: Topical GH accelerated wound closure and selected repair histology in mice compared with vehicle.

Does not show: Local GH in one skin-wound species does not demonstrate injected secretagogue stack benefit or endogenous necessity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[43] Effect of growth hormone therapy in burn patients on conservative treatment.

Shows: A small comparative burn series reported better wound healing and other clinical measures with GH plus conservative care, alongside metabolic adverse changes.

Does not show: Thirteen treated and nine control patients with nonrandomized allocation cannot establish a reliable mortality benefit or general healthy-adult recovery effect.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

[44] Human growth hormone may be detrimental when used to accelerate recovery from acute tendon-bone interface injuries.

Shows: Randomized rat rotator-cuff repair experiments found no benefit of postoperative GH and worse ultimate failure load with prolonged high-dose perioperative GH.

Does not show: The harm is specific to an animal tendon-bone injury and high dosing; it does not prove every human peptide formulation harms tendons.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

[45] Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts.

Shows: Injured mouse muscle increased thymosin beta 4 expression, and peptide forms increased myoblast chemotaxis and cell-culture wound closure.

Does not show: Expression and cellular migration do not establish endogenous necessity, full in-vivo muscle recovery or human injected peptide efficacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[46] Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.

Shows: A thirty-two-rat Achilles repair study found a significant mechanical advantage for TB-500 alone; combined BPC-157/TB-500 did not confer additional benefit over individual treatment.

Does not show: This recent four-arm animal experiment tests another exact stack, not CJC-ipamorelin; small groups and four-week surgical model do not establish human efficacy, safety or dose equivalence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

[47] Thymosin beta4 accelerates wound healing.

Shows: Topical or intraperitoneal full-length thymosin beta 4 improved rat skin reepithelialization and contraction, with increased collagen and angiogenesis.

Does not show: Rat skin closure and cultured keratinocyte migration do not establish marketed TB-500 identity or healthy-adult CJC-ipamorelin recovery.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[48] Thymosin β4 enhances the healing of medial collateral ligament injury in rat.

Shows: Local thymosin beta 4 in fibrin sealant improved four-week rat medial-collateral-ligament histology and biomechanical properties.

Does not show: Local delivery, animal injury and another molecule limit translation; it is not a controlled human stack or proof of systemic safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[49] Effects of thymosin β4 on wound healing of rat palatal mucosa.

Shows: Thymosinbeta 4 enhanced rat palatal-wound closure and primary-cell migration, with MMP 2 and VEGF changes.

Does not show: Small animal and cell assays show partial repair support, not a human functional recovery or exact-stack clinical outcome.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[50] Recombinant thymosin beta 4 can promote full-thickness cutaneous wound healing.

Shows: An originally produced recombinant human thymosin beta 4 preparation promoted full-thickness wound healing in mice.

Does not show: Recombinant expression was a production method, not endogenous necessity; product, route and animal scope prevent clinical stack inference.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[51] Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.

Shows: A blinded 65-person MK-677 trial increased GH, IGF-I and fat-free mass over twelve months but showed no significant strength or function improvement; glucose rose and insulin sensitivity fell.

Does not show: Primary power focused on fat-free mass and visceral fat; secondary functional nulls do not establish equivalence, and another oral agent and older population do not test the exact stack.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHODS:paragraph0, 1:METHODS:paragraph1, 1:METHODS:paragraph10, 1:METHODS:paragraph11, 1:METHODS:paragraph18, 1:METHODS:paragraph19, 2:RESULTS:paragraph4, 2:RESULTS:paragraph5, 2:RESULTS:paragraph15, 2:RESULTS:paragraph16, 2:RESULTS:paragraph20, 2:RESULTS:paragraph21. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3, SC4.

[52] The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial.

Shows: A blinded ninety-six-athlete trial found an approximately 3.9 percent GH-associated sprint-capacity increase over eight weeks, with no significant strength, aerobic endurance or jump-power change; lean-mass gain largely reflected extracellular water.

Does not show: Different hormones and a performance endpoint do not test exact peptide recovery; sprint gain was not maintained after six-week washout, and athletic importance and safety were uncertain.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

[53] Effect of growth hormone and resistance exercise on muscle growth in young men.

Shows: In sixteen young men randomized to identical resistance training with GH or placebo, GH increased fat-free mass and whole-body synthesis but did not add muscle-strength or quadriceps-synthesis gain over twelve weeks.

Does not show: Small trial and recombinant GH differ from the exact stack; similar training gains do not prove all GH-axis exposures ineffective or establish equivalence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[54] Effect of growth hormone and resistance exercise on muscle growth and strength in older men.

Shows: In twenty-three older men assigned to the same resistance training with GH or placebo, fat-free mass and water rose more with GH but muscle protein synthesis and strength increments were similar.

Does not show: The trial supplies a proxy-versus-function and concurrent-training boundary; another molecule and small unequal groups do not test exact-combination recovery.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[55] Increased mortality associated with growth hormone treatment in critically ill adults.

Shows: Two blinded trials in 532 critically ill adults found higher mortality with high-dose GH: 39 versus 20 percent and 44 versus 18 percent; survivors also had longer ventilation and stays.

Does not show: This is a serious randomized safety boundary for high-dose GH in prolonged critical illness, not a measured mortality rate for healthy-adult CJC-ipamorelin stacks.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[56] Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial.

Shows: A blinded 131-person older-adult factorial GH/sex-steroid trial increased lean mass; combined GH-testosterone improved men's VO2 max, while women's strength/endurance were not significantly improved and metabolic or edema-related adverse events were frequent.

Does not show: Different hormone combination, sex-specific responses and 26-week exposure do not establish exact-stack recovery; lean mass alone and correlational changes do not identify mediation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.md
• CONSENSUS_CROSSCHECK.html
• CONSENSUS_CROSSCHECK.md
• RESEARCH_TIMELINE.html
• RESEARCH_TIMELINE.md
• SHA256.txt
• adversarial-findings.json
• codex-correction-provenance.json
• consensus-validation.json
• edition-approval-audit.json
• peptide-stacks-recovery.review.md
• peptide-stacks-recovery.scorecard.json
• reader-summary.json
• research-timeline.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt
• video-insert.md
• web-page.md

Sources: 56 · load-bearing claims: 61 · verified: 61 · unverified: 0 · contradicted: 0 · schema 5.3